Whalesbook
Credit Rating Reaffirmation for Haleos Labs and Mahi Drugs
Haleos Labs Limited, formerly SMS Lifesciences India Limited, and its subsidiary Mahi Drugs Private Limited have received reaffirmed credit ratings from Infomerics Valuation and Rating Limited. The ratings cover their fund-based and non-fund-based bank facilities.
What Happened
Haleos Labs' long-term rating was reaffirmed at IVR BBB/Positive, and its short-term rating at IVR A3+. The company's total rated bank loan facilities have been increased to Rs 116.01 crore from Rs 81.86 crore.
Mahi Drugs Private Limited, a key subsidiary, maintained its long-term rating at IVR BB+/Stable. Its total rated bank loan facilities were boosted to Rs 20.75 crore from Rs 10.83 crore.
Why It Matters
These reaffirmed ratings suggest a stable financial outlook for both companies, indicating their ability to meet debt obligations. The increase in loan facilities points to potential expansion plans or growing working capital needs, which could be viewed positively by the market if linked to business growth.
Company Background
Haleos Labs, previously known as SMS Lifesciences India Limited, operates in the pharmaceutical sector, focusing on drug development and manufacturing.
Future Outlook
The reaffirmation offers continued confidence to lenders and investors about the creditworthiness of Haleos Labs and Mahi Drugs. The larger bank loan facilities may provide the necessary support for future growth initiatives.
Potential Risks
While the current ratings are positive, any future decline in financial performance or a substantial rise in debt levels could affect these credit assessments. Infomerics will continue to monitor the credit quality through periodic surveillance.
Key Figures
- Haleos Labs Rated Facilities: Rs 116.01 Crore (Enhanced)
- Mahi Drugs Rated Facilities: Rs 20.75 Crore (Enhanced)
- Rating Validity: Until May 20, 2027
What to Watch
Investors should keep an eye on the companies' financial results and how they utilize the increased bank loan facilities. Any new rating updates from Infomerics will also be important to track.